Last reviewed · How we verify
NCT04787952
Insight Into New Brown Adipose Tissue Activators.
trial testing cold expossure in Adiposity in 40 participants. Completed in 24 February 2018.
24 February 2018
Quick facts
| Lead sponsor | Medical University of Bialystok |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 October 2016 |
| Primary completion | 24 February 2018 |
| Estimated completion | 24 February 2018 |
Drugs / interventions tested
- cold expossure
Conditions studied
- Adiposity — all drugs for Adiposity →
- Metabolic Complication — all drugs for Metabolic Complication →
- Metabolic Disturbance — all drugs for Metabolic Disturbance →
- Healthy — all drugs for Healthy →
Sponsor
Medical University of Bialystok
Who can join
Adults 20 to 43, male only, with Adiposity or Metabolic Complication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The general purpose of the study was to provide new information about the role of macronutrients intake, metabolomics, proteomics and microRNA on BAT activation. The invesigator evaluated BAT activity and whole body energy consumption under cold stimulation in two gruops of healthy males aged 21-43 years old with normal BMI ( 19-25kg/m2) and in overweight/obese subjects.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery.
Pandey A, Ajgaonkar S, Jadhav N, Saha P, et al · · 2022 · cited 14× · PMID 36297381 · DOI 10.3390/ph15101269
Verify or expand the search:
- PubMed search for NCT04787952
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adiposity
Currently open trials in the same condition.
- NCT06532747 — Redefining BMI: The Body, Mind, and Inflammation Trial · NA · recruiting
- NCT07103343 — MOVI-OLE! [Open Learning Environments] · NA · active not recruiting
- NCT06264882 — Cardiometabolic Consequences of the Loss of Ovarian Function · Phase 4 · recruiting
- NCT06208345 — Early Life Intervention in Pediatrics Supported by E-health · NA · recruiting
- NCT06129110 — Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling · NA · recruiting
Other Medical University of Bialystok trials
Trials by the same sponsor.
- NCT07496957 — Preserflo MicroShunt Versus Trabeculectomy · NA · recruiting
- NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
- NCT07325552 — iStent Inject Versus Goniotomy With Kahook Dual Blade in Glauocma Treatment · NA · recruiting
- NCT07529145 — Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment · recruiting
- NCT06855979 — The Impact of Dietary Intervention on Oxidative/antioxidant Markers and Gut Microbiota in Athletes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04787952 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Bialystok
- Last refreshed: 10 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04787952.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing